ADVM - NASDAQ
Adverum Biotechnologies, Inc.
$4.36
+0.0000%Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
At a Glance
Live Snapshotadvm
Cash and Short Term Investments
Last Annual Value
125.69M
3-Year CAGR
-26%
5-Year CAGR
-5%
10-Year CAGR
-2%
Adverum Biotechnologies, Inc. Competitors Analysis of Cash and Short Term Investments
| Company | Cash and Short Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Adverum Biotechnologies, Inc. NASDAQ:ADVM | 125.69M | 9.2% | -16.3% | -5.5% | |
 Biomea Fusion, Inc. NASDAQ:BMEA | 55.81M | -31.9% | -20.3% | N/A | |
 Sutro Biopharma, Inc. NASDAQ:STRO | 141.43M | -27.8% | -6.5% | 11.5% | |
 Adicet Bio, Inc. NASDAQ:ACET | 158.53M | -0.2% | -10.6% | 8.9% | |
 Spruce Biosciences, Inc. NASDAQ:SPRB | 48.91M | -20.2% | -11.3% | N/A | |
 Kalaris Therapeutics Inc NASDAQ:KLRS | 117.98M | 233.9% | -13.8% | N/A | |
 Oramed Pharmaceuticals Inc. NASDAQ:ORMP | 125.89M | -8.1% | 6.0% | 15.0% | |
 Surrozen, Inc. NASDAQ:SRZN | 89.25M | 35.3% | -2.6% | N/A | |
 aTyr Pharma, Inc. NASDAQ:ATYR | 78.69M | -7.1% | -6.1% | 0.9% | |
 Artiva Biotherapeutics, Inc. NASDAQ:ARTV | 108.01M | 12.0% | -7.7% | N/A | |
 Precision BioSciences, Inc. NASDAQ:DTIL | 115.58M | -0.3% | -4.3% | 2.2% |
Adverum Biotechnologies, Inc. Fair Value Envelope
Related Guides
Continue your ADVM research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.